Abstract

Osteopontin (OPN) is a multifunctional cytokine that can impact cancer progression. Therefore, it is crucial to determine the key factors involved in the biological role of OPN for the development of treatment. Here, we investigated that OPN promoted hepatocellular carcinoma (HCC) cell proliferation and migration by increasing Reactive oxygen species (ROS) production and disclosed the underlying mechanism. Knockdown of OPN suppressed ROS production in vitro and in vivo, whereas treatment with human recombinant OPN produced the opposite effect. N-Acetyl-L-cysteine (NAC, ROS scavenger) partially blocked HCC cell proliferation and migration induced by OPN. Mechanistically, OPN induced ROS production in HCC cells by upregulating the expression of NADPH oxidase 1 (NOX1). NOX1 knockdown in HCC cells partially abrogated the cell proliferation and migration induced by OPN. Moreover, inhibition of JAK2/STAT3 phosphorylation effectively decreased the transcription of NOX1, upregulated by OPN. In addition, NOX1 overexpression increased JAK2 and STAT3 phosphorylation by increasing ROS production, creating a positive feedback loop for stimulating JAK2/STAT3 signaling induced by OPN. This study for the first time demonstrated that HCC cells utilized OPN to generate ROS for tumor progression, and disruption of OPN/NOX1 axis might be a promising therapeutic strategy for HCC.

Details

Title
Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2/STAT3/NOX1-mediated ROS production
Author
Wu, Qipeng 1 ; Li, Le 1 ; Miao Chunmeng 1 ; Hasnat Muhammad 2 ; Sun, Lixin 1 ; Jiang Zhenzhou 3   VIAFID ORCID Logo  ; Zhang Luyong 4   VIAFID ORCID Logo 

 China Pharmaceutical University, New drug screening center, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 University of Veterinary and Animal Sciences, Institute of Pharmaceutical Sciences, Lahore, Pakistan (GRID:grid.412967.f) (ISNI:0000 0004 0609 0799) 
 China Pharmaceutical University, New drug screening center, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793); China Pharmaceutical University, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 China Pharmaceutical University, New drug screening center, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793); Guangdong Pharmaceutical University, The Center for Drug Research and Development, Guangzhou, China (GRID:grid.411847.f) (ISNI:0000 0004 1804 4300) 
Publication year
2022
Publication date
Apr 2022
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2649849437
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.